All vaccinated racial and ethnic groups had lower mortality risks than did unvaccinated comparison groups. Discussion In a cohort of 6.4 million COVID-19 vaccinees and 4.6 million demographically similar unvaccinated persons, recipients of the Pfizer-BioNTech, Moderna, or Janssen vaccines had lower non–COVID-19 mortality risk than did the unvaccinated comparison groups. There is no increased risk for mortality among COVID-19 vaccine recipients. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States. The lower mortality risk after COVID-19 vaccination suggests substantial healthy vaccinee effects (i.e., vaccinated persons tend to be healthier than Morbidity and Mortality Weekly Report 1522 MMWR / October 29, 2021 / Vol. 70 / No. 43 US Department of Health and Human Services/Centers for Disease Control and Prevention TABLE 1. Abbreviations: Janssen = Johnson & Johnson; NA = not applicable. * Among Pfizer-BioNTech COVID-19 vaccine recipients, 2,980,152 received the second dose by May 31, 2021; among Moderna COVID-19 vaccine recipients, 2,362,157 received the second dose by May 31, 2021. †Unvaccinated comparison group included unvaccinated persons and COVID-19 vaccine recipients before COVID-19 vaccination. The assignment of index dates allowed COVID-19 vaccinees to contribute unvaccinated person-time before vaccination, thus avoiding immortal time bias. § mRNA vaccines included Pfizer-BioNTech and Moderna COVID-19 vaccines. unvaccinated persons) (7,8), which will be explored in future analyses. Mortality rates among Janssen vaccine recipients were not as low as those among mRNA vaccine recipients. This finding might be because of differences in risk factors, such as underlying health status and risk behaviors among recipients of mRNA and Janssen vaccines that might also be associated with mortality risk.
unvaccinated persons) (7,8), which will be explored in future analyses. Mortality rates among Janssen vaccine recipients were not as low as those among mRNA vaccine recipients. This finding might be because of differences in risk factors, such as underlying health status and risk behaviors among recipients of mRNA and Janssen vaccines that might also be associated with mortality risk.
This report describes lower non-COVID-19 death rates among COVID-19 vaccinated people.
www.cdc.gov